2 1 Shi Ji Jing Ji Bao Dao·2025-12-19 08:33Core Viewpoint - BeiGene has made significant changes to its core management team, establishing a "dual president" position in the pharmaceutical industry with the appointment of Dr. Wang Lai as President while retaining his role as Global Head of R&D [1] Group 1: Management Changes - Dr. Wang Lai has been appointed as President of BeiGene, overseeing R&D, business development, and alliance management [1] - Dr. Wu Xiaobin remains in his position as President and Chief Operating Officer, indicating a unique dual leadership structure within the company [1] - The company previously underwent a major personnel change in August, with the appointment of Shan Guohong as General Manager for Greater China, Central Asia, and South Asia, reporting to Dr. Wu Xiaobin [1] Group 2: Clarifications and Future Communication - BeiGene has addressed concerns regarding Dr. Wu Xiaobin's position, stating that he remains a core management member and any future changes will be disclosed promptly [1]